Loading...
XSHG603567
Market cap1.41bUSD
Jan 15, Last price  
11.01CNY
1D
-0.36%
1Q
-1.52%
Jan 2017
-44.28%
IPO
-41.09%
Name

HeiLongJiang ZBD Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:603567 chart
P/E
21.87
P/S
3.29
EPS
0.50
Div Yield, %
1.53%
Shrs. gr., 5y
2.05%
Rev. gr., 5y
2.45%
Revenues
3.14b
-25.50%
1,071,278,3651,379,697,2201,414,805,4311,592,911,2482,073,059,8622,391,577,9663,140,871,7722,785,643,5523,296,780,7543,410,854,7604,129,954,2264,219,403,2683,143,513,397
Net income
473m
+154.93%
296,063,699389,646,158436,904,115477,300,085585,305,007509,560,904520,872,588462,436,499408,648,864436,285,785332,099,672185,440,370472,740,021
CFO
-458m
104,713,774154,247,334174,683,626386,323,632015,825,550853,192,181367,403,246220,922,861155,178,02500-457,897,889
Dividend
Jul 12, 20240.2 CNY/sh
Earnings
May 20, 2025

Profile

Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthopedics, tumors, digestive system, anti-infection, mental nerve, genitourinary, and other disease fields. The company was founded in 1996 and is based in Hulin, China.
URL
http://www.zbdzy.com/
IPO date
Apr 24, 2015
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,143,513
-25.50%
4,219,403
2.17%
Cost of revenue
2,687,599
4,265,891
Unusual Expense (Income)
NOPBT
455,914
(46,488)
NOPBT Margin
14.50%
Operating Taxes
10,760
107,604
Tax Rate
2.36%
NOPAT
445,154
(154,092)
Net income
472,740
154.93%
185,440
-44.16%
Dividends
(158,280)
(99,848)
Dividend yield
1.38%
0.83%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,848,873
2,456,298
Long-term debt
1,298,277
479,919
Deferred revenue
169,343
181,882
Other long-term liabilities
345,917
46,375
Net debt
427,471
711,985
Cash flow
Cash from operating activities
(457,898)
CAPEX
(95,138)
Cash from investing activities
176,427
283,931
Cash from financing activities
765,692
FCF
(457,086)
(172,851)
Balance
Cash
1,454,467
1,001,898
Long term investments
1,265,211
1,222,335
Excess cash
2,562,503
2,013,262
Stockholders' equity
5,721,062
4,787,250
Invested Capital
8,971,080
8,049,195
ROIC
5.23%
ROCE
3.94%
EV
Common stock shares outstanding
940,028
941,547
Price
12.16
-4.63%
12.75
-16.67%
Market cap
11,430,739
-4.78%
12,004,728
-9.25%
EV
12,350,481
12,724,648
EBITDA
646,353
122,512
EV/EBITDA
19.11
103.86
Interest
135,413
138,680
Interest/NOPBT
29.70%